Enanta Pharmaceuticals, Inc.

225 articles with Enanta Pharmaceuticals, Inc.

• Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)

  6/14/2019

  EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo

• Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences - June 10, 2019

  6/10/2019

  Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences

• Enanta Pharmaceuticals to Present at Upcoming Investor Conference

  5/14/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation format at the following investor conference:

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

  5/7/2019

  Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019

• Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

  4/22/2019

  Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2019 after the U.S. markets close on May 7, 2019.

• Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019

  4/11/2019

  Enanta Pharmaceuticals, Inc. announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B virus and non-alcoholic steatohepatitis will be presented at The International Liver Congress™ 2019, in Vienna, Austria.

• Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019

  3/27/2019

  Enanta Pharmaceuticals, Inc. announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH) have been accepted for presentations at The International Liver Congress™ (ILC) 2019, April 10-14, in Vienna, Austria.

• Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

  3/18/2019

  Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced it has completed enrollment in two Phase 2 studies.

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

  2/6/2019

  Research and development programs progressing well with clinical milestones expected in 2019 in our RSV, NASH, and HBV programs

• Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018

  1/22/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2018 after the U.S. markets close on February 6, 2019.

• Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus

• Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

  12/20/2018

  Presentation and Question and Answer Session to be Webcast beginning at 4:30 p.m. PT on January 7, 2019

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

  11/26/2018

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2018. “

• Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

  11/13/2018

  EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)1

• Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

  10/29/2018

  Enanta Pharmaceuticals, Inc. today announced that it plans to report its financial results for its fiscal fourth quarter and fiscal year ended September 30, 2018, on November 26, 2018.

• Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

  10/23/2018

  Study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 against respiratory syncytial virus infection in a human challenge study.

• Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018

  8/7/2018

  Webcast and Conference Call today at 4:30 p.m. ET

• Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018

  7/16/2018

  Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2018, after the U.S. markets close on August 7, 2018

• Enanta Pharmaceuticals Recognizes the 1st International NASH Day

  6/12/2018

  Enanta Pharmaceuticals, Inc. is proud to support the 1st International NASH Day taking place today.

• BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors

  6/12/2018

  BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.